85. 特発性間質性肺炎 Idiopathic interstitial pneumonia Clinical trials / Disease details

臨床試験数 : 627 / 薬物数 : 443 - (DrugBank : 120) / 標的遺伝子数 : 99 - 標的パスウェイ数 : 212

91 trials found

diseases per page:

Showing 1 to 10 of 91 diseases

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT05195918 (ClinicalTrials.gov)	March 1, 2023	2/12/2021	Study of Oral Epigallocatechin-3-gallate (EGCG) in IPF Patients	Dose Ranging Study of Oral Epigallocatechin-3-gallate (EGCG) Given Daily for 12 Weeks to Patients Wi ...	Idiopathic Pulmonary Fibrosis	Combination Product: EGCG 300 mg + Nintedanib;Combination Product: EGCG 300 mg + Pirfenidone;Combina ...	Hal Chapman	University of Michigan;Cornell University;Massachusetts General Hospital;Temple University;Universit ...	Not yet recruiting	40 Years	85 Years	All	50	Phase 1	United States
2	EUCTR2021-006820-41-GR (EUCTR)	23/12/2022	16/09/2022	A Randomized Double-blind Trial to Evaluate the Efficacy, Tolerability, Safety and Dose Response of ...	A Randomized Double-blind, Four-Arm Active and Placebo-controlled Dose-Finding Trial to Evaluate the ...	Idiopathic Pulmonary Fibrosis (IPF);Therapeutic area: Diseases [C] - Respiratory Tract Diseases [C08 ...	Product Name: deupirfenidone Product Code: LYT-100 INN or Proposed INN: deupirfenidone Other descriptiv ...	PureTech LYT 100, Inc.	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	240	Phase 2	Serbia;United States;Czechia;Taiwan;Greece;Thailand;Chile;Colombia;India;Mexico;Argentina;Malaysia;P ...
3	NCT05428150 (ClinicalTrials.gov)	August 8, 2022	15/6/2022	Randomized, Crossover, Multi-Dose Pharmacokinetics of EXCL-100 Pirfenidone-Sustained Release Tablet ...	Randomized, Crossover, Multi-Dose, Steady State, Comparative Pharmacokinetics and Relative Bioavaila ...	Idiopathic Pulmonary Fibrosis	Drug: Esbriet 267 MG Oral Capsule;Drug: EXCL-100, 600 MG Oral Tablet	Excalibur Pharmaceuticals, Inc.	NULL	Completed	18 Years	65 Years	All	32	Phase 1	United States
4	NCT05321420 (ClinicalTrials.gov)	July 29, 2022	2/4/2022	LYT-100 in Patients With Idiopathic Pulmonary Fibrosis (IPF)	A Randomized Double-blind, Four-Arm Active and Placebo-controlled Dose-Finding Trial to Evaluate the ...	Idiopathic Pulmonary Fibrosis	Drug: Placebo;Drug: Pirfenidone;Drug: Deupirfenidone	PureTech	NULL	Recruiting	40 Years	N/A	All	240	Phase 2	United States;Argentina;Georgia;Greece;India;Malaysia;Romania;Thailand
5	NCT05373914 (ClinicalTrials.gov)	May 31, 2022	10/5/2022	RESPIRARE - Efficacy and Safety of Cudetaxestat in Patients With Idiopathic Pulmonary Fibrosis (IPF) ...	RESPIRARE - A Phase 2, Randomized, Double-blinded, Placebo-controlled, Efficacy and Safety Study of ...	Idiopathic Pulmonary Fibrosis	Drug: Cudetaxestat (BLD-0409);Drug: Control: Matching Placebo	Blade Therapeutics	NULL	Not yet recruiting	40 Years	85 Years	All	200	Phase 2	NULL
6	NCT04888715 (ClinicalTrials.gov)	July 23, 2021	28/4/2021	To Evaluate Drug-drug Interactions Between DWN12088 and Pirfenidoneor Nintedanib in Healthy Voluntee ...	An Open Label, 2-part, One-sequence, 3-period Study to Evaluate Drug-drug Interactions Between DWN12 ...	Idiopathic Pulmonary Fibrosis	Drug: DWN12088;Drug: Pirfenidone;Drug: Nintedanib	Daewoong Pharmaceutical Co. LTD.	NULL	Completed	19 Years	55 Years	All	48	Phase 1	Korea, Republic of
7	NCT05383131 (ClinicalTrials.gov)	June 23, 2021	12/5/2022	To Evaluate Drug-drug Interactions Between HEC585 and Pirfenidoneor Nintedanib in Healthy Volunteers ...	A Single Center, Open Label Study to Evaluate Drug-drug Interactions Between HEC585 and Pirfenidoneo ...	Idiopathic Pulmonary Fibrosis	Drug: HEC585;Drug: Pirfenidone;Drug: Nintedanib	Sunshine Lake Pharma Co., Ltd.	NULL	Completed	18 Years	45 Years	All	33	Phase 1	China
8	EUCTR2020-005103-39-PL (EUCTR)	24/04/2021	24/03/2021	Access to PirfenidoneSolution for Inhalation (AP01) for Treatment of Progressive, Fibrosing Intersti ...	Access to PirfenidoneSolution for Inhalation (AP01) for Treatment of Progressive, Fibrosing Intersti ...	Interstitial Lung Diseases (ILD), including but not limited to idiopathic pulmonary fibrosis (IPF) M ...	Product Name: Pirfenidone Solution for Inhalation Product Code: AP01 INN or Proposed INN: PIRFENIDONE Ot ...	Avalyn Pharma, Inc.	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	100	Phase 2	Czechia;Czech Republic;Poland;Australia;Netherlands;United Kingdom;New Zealand
9	EUCTR2020-005103-39-NL (EUCTR)	21/04/2021	07/01/2021	Access to PirfenidoneSolution for Inhalation (AP01) for Treatment of Progressive, Fibrosing Intersti ...	Access to PirfenidoneSolution for Inhalation (AP01) for Treatment of Progressive, Fibrosing Intersti ...	Interstitial Lung Diseases (ILD), including but not limited to idiopathic pulmonary fibrosis (IPF) M ...	Product Name: Pirfenidone Solution for Inhalation Product Code: AP01 INN or Proposed INN: PIRFENIDONE Ot ...	Avalyn Pharma, Inc.	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	100	Phase 2	Czechia;Czech Republic;Poland;Australia;Netherlands;United Kingdom;New Zealand
10	EUCTR2020-005103-39-CZ (EUCTR)	16/04/2021	22/12/2020	Access to PirfenidoneSolution for Inhalation (AP01) for Treatment of Progressive, Fibrosing Intersti ...	Access to PirfenidoneSolution for Inhalation (AP01) for Treatment of Progressive, Fibrosing Intersti ...	Interstitial Lung Diseases (ILD), including but not limited to idiopathic pulmonary fibrosis (IPF) M ...	Product Name: Pirfenidone Solution for Inhalation Product Code: AP01 INN or Proposed INN: PIRFENIDONE Ot ...	Avalyn Pharma, Inc.	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	100	Phase 2	Czechia;Czech Republic;Poland;Australia;Netherlands;United Kingdom;New Zealand

First Previous1 2 3 4 5…10Next Last